The University of Notre Dame’s Warren Family Research Center for Drug Discovery and Development is focusing on collaboration, as it continues a rich history in therapeutic discovery.
Coinciding with the World Rare Disease Day, Notre Dame acknowledges a recent, generous gift from Notre Dame parents David and Cathleen Reisenauer of Morgan Hill, Calif., which will allow the Warren Family Research Center for Drug Discovery and Development to initiate a new area of research, focusing on the rare disease glycogen storage disease type III (GSDIII), also known as Cori Disease.
Rare Disease Day takes place annually on the last day of February. Its goal is to raise awareness amongst the general public and policy-makers. Global Genes maintains the RARE List™ of 7,000 rare diseases defined in the United States where a prevalence of less than 200,000 cases is the primary criteria. With about 25M Americans affected by a rare disease and the potential to increase our understanding of more common afflictions, rare disease research is a key to better health for all of us.…
For decades, professor Paul Helquist has partnered with colleagues in Sweden to send undergraduate and graduate chemistry students to each others’ laboratories—around 50 in total—to perform research at Notre Dame, the University of Stockholm, Gothenburg University, the Royal Institute of Technology in Stockholm as well as the Astra Zeneca pharmaceutical lab near Gothenburg. Students from Notre Dame obtain valuable experience working in an international lab in a country which has a long-standing, strong program in science and engineering, particularly chemistry.
The Office of Technology Transfer (OTT) is now accepting nominations for the 1st Source Bank Technology Commercialization competition. The winner will be revealed at the seventh annual commercialization event on April 18, 2017, and will receive a $20,000 cash award.